New Amsterdam Partners LLC NY raised its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 17.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,536 shares of the biotechnology company’s stock after buying an additional 9,939 shares during the period. New Amsterdam Partners LLC NY’s holdings in Anika Therapeutics were worth $3,234,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atria Investments LLC increased its position in Anika Therapeutics by 1.2% in the second quarter. Atria Investments LLC now owns 5,631 shares of the biotechnology company’s stock worth $278,000 after buying an additional 68 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Anika Therapeutics by 0.3% in the second quarter. Rhumbline Advisers now owns 27,720 shares of the biotechnology company’s stock valued at $1,368,000 after buying an additional 96 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Anika Therapeutics by 1.7% in the first quarter. Louisiana State Employees Retirement System now owns 6,000 shares of the biotechnology company’s stock valued at $261,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System increased its stake in shares of Anika Therapeutics by 1.3% in the first quarter. Arizona State Retirement System now owns 7,590 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 100 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its stake in shares of Anika Therapeutics by 3.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 100 shares in the last quarter. Institutional investors own 81.27% of the company’s stock.

Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 51.72 on Friday. The company has a market capitalization of $758.11 million, a P/E ratio of 22.98 and a beta of 1.69. The company has a 50-day moving average of $49.30 and a 200 day moving average of $47.05. Anika Therapeutics Inc. has a 12 month low of $41.38 and a 12 month high of $53.99.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.32. The business had revenue of $33.50 million for the quarter, compared to the consensus estimate of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The firm’s quarterly revenue was up 25.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.57 EPS. Analysts forecast that Anika Therapeutics Inc. will post $2.00 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/13/new-amsterdam-partners-llc-ny-acquires-9939-shares-of-anika-therapeutics-inc-anik.html.

ANIK has been the topic of several recent research reports. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $50.03, for a total transaction of $710,476.03. Following the transaction, the chief executive officer now directly owns 246,740 shares in the company, valued at approximately $12,344,402.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Charles H. Sherwood sold 63,799 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the transaction, the chief executive officer now owns 174,705 shares in the company, valued at $8,873,266.95. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 88,725 shares of company stock worth $4,459,085. Corporate insiders own 6.57% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Stock Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related stocks with our FREE daily email newsletter.